Evogene, a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, Israel, has announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company.
The initiative is designed to support scientific entrepreneurs and research teams that possess deep biological understanding of novel disease targets but often face significant challenges in translating these discoveries into viable drug development programmes.
By combining BCDD's advanced experimental infrastructure and translational drug discovery capabilities with Evogene's AI-driven computational chemistry generative engine, ChemPass AI™, the collaboration seeks to create a powerful acceleration framework that bridges the gap between biological insight and drug candidate development.
Many promising academic discoveries fail to progress due to the lack of integrated capabilities required for early-stage drug discovery. This joint initiative directly addresses these challenges by providing entrepreneurs with access to both computational and experimental resources under a coordinated development framework.
